KLRK1 and hepatocellular carcinoma: A NKG2D-based CAR-T cell therapy has been developed for the treatment of relapsed or refractory NKG2DL+ solid tumors [197] and a phase I clinical trial focus on HCC is ongoing [NCT04550663; NCT05131763].